Inossia raises $8.84M, holds half pending FDA clearance
What's the deal? Swedish medtech InossiaDealroom has a profile for this one. Try Dealroom → has raised US$10.6M (≈$8.84 million) in a growth equity round led by Cradle Growth and the EIC Fund. The company develops a softening additive for bone cement used to treat spinal fractures.
How it's structured: The oversubscribed round combines a rights issue for existing shareholders with a directed issue to select investors. About half the capital is paid upfront; the rest is committed upon FDA clearance in the US.
What's the endgame? Inossia's Cement Softener mixes with approved PMMA-based bone cement to match the stiffness of natural bone, aiming to cut the risk of future vertebral fractures. With current treatments, up to 40% of patients suffer new fractures.
Why now? The company holds FDA Breakthrough Device Designation, granted in 2025, and plans to submit for US clearance within 12 months. The funding will complete its studies and support commercialisation and international expansion.
The raise follows a smaller, oversubscribed US$1.25M rights issue in 2025 — a notable step-up in funding. Cradle Growth is a relatively new Nordic growth equity and venture capital firm whose other investments include SuturionDealroom has a profile for this one. Try Dealroom → and CuvivaDealroom has a profile for this one. Try Dealroom →.
What could go wrong? The second tranche hinges on FDA clearance, and Breakthrough Device Designation offers priority interaction, not approval. The commercial case still rests on trial results testing whether the softer cement reduces subsequent fractures.
The signal: By tying half the money to a regulatory milestone, the deal shows investors backing medtech while hedging on clinical and regulatory risk. "The fact that we are able to attract investors at this stage who both understand the product's potential and are willing to invest is a strong validation of the work we have accomplished so far," said chief executive officer Malin Nilsson.
Read more: lifesciencefocus.com
Image credit: Semtrio
